Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States.

ABSTRACT:

Background

Spinal muscular atrophy (SMA) is a progressive, devastating disease and a leading inherited cause of infant mortality. The limited population-based literature is confined to small regional studies. Estimates of prevalence are needed to characterize the burden of SMA and to understand trends in prevalence by disease type as new treatments become available. The reported estimates of SMA genotype prevalence at birth consistently range from 8.5-10.3 per 100,000 live births, with a mid-range estimate of 9.4 per 100,000. Among infants born with an SMA genotype, it is reported that ~58% will develop SMA Type I, 29% will develop Type II, and 13% will develop Type III, respectively.

Results

Using evidence from peer-reviewed literature for SMA birth prevalence, age at sympt

SUBMITTER: Lally C 

PROVIDER: S-EPMC5704427 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature